|
WO2011156811A2
|
|
Compounds for treatment of bovine mastitis
|
|
WO2008098374A1
|
|
Salts, prodrugs and polymorphs of fab i inhibitors
|
|
WO2008009122A1
|
|
Acrylamide derivatives as fab i inhibitors
|
|
WO2007064865A2
|
|
Fabg polypeptides ( 3-oxoacyl- [ acyl-carrier protein ] reductase ) involved in bacterial fatty acid synthesis
|
|
EP1973902A2
|
|
3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
|
|
WO2007064829A2
|
|
Novel purified polypeptides involved in bacterial fatty acid biosynthesis
|
|
CN101415701A
|
|
Heterocyclylacrylamide compounds as FABI inhibitors and antibacterial agents
|
|
WO2007064821A2
|
|
Purified fabh polypeptides involved in bacterial fatty acid synthesis
|
|
WO2007093848A2
|
|
Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
|
|
US2006078974A1
|
|
Novel purified hydroxymethylglutaryl-CoA reductases and structures thereof
|
|
US2007048814A1
|
|
Novel Purified dihydrodipicolinate synthase polypeptides and structures thereof
|
|
WO2006008660A2
|
|
Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
|
|
WO2006028561A2
|
|
Novel purified fabi polypeptides from fransicella tularensis
|
|
US2007072192A1
|
|
Novel polypeptides encoded by essential bacterial genes
|
|
CA2481452A1
|
|
Novel purified polypeptides from streptococcus pneumoniae
|
|
US2005181388A1
|
|
Novel purified polypeptides from bacteria
|
|
US2005181464A1
|
|
Novel purified polypeptides from bacteria
|
|
CA2476028A1
|
|
Novel purified polypeptides from staphylococcus pneumoniae
|
|
CA2479104A1
|
|
Methods and apparatuses for characterizing refolding and aggregation of biological molecules
|
|
US2005079526A1
|
|
Methods and apparatuses for characterizing refolding and aggregation of biological molecules
|
